Comparison of bone scan with carbohydrate antigen 15-3 for evaluation of bone metastasis of brest cancer

Pakistan Journal of Biological Sciences

Volumn 13, Issue 4, 2010, Pages 175-179

  Mohammadzadeh, M ^a   Alikhah, H ^a   Zareh, A G A ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metastasis; Oncology; Scintigraphy; Tumor marker

Indexed keywords

MUCIN 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE TUMOR; BREAST TUMOR; FEMALE; HUMAN; IRAN; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IRAN; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649291245     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2010.175.179     Document Type: Article

References (30)

1. Agyei Frempong, M.T., E. Darko and B.W. Addai, 2008. The use of Carbohydrate Antigen (CA) 15-3 as a tumor marker in detecting breast cancer. Pak. J. Biol. Sci., 11: 1945-1948.
2. Arslan, N., M. Serdar, S. Deveci, B. Ozturk and Y. Narin et al., 2000. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis. Ann. Nucl. Med., 14: 395-399.
3. Buffaz, P.D., A.S. Gauchez, J.P. Caravel, J.P. Vuillez, C. Cura, C. Agnius-Delord and D. Fagret, 1999. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur. J. Nucl. Med., 26: 8-11.
4. Cook, G.J. and I. Fogelman, 1999. Skeletal metastases from breast cancer: Imaging with nuclear medicine. Semin. Nucl. Med., 29: 69-79.
5. Duncan, J.L., A. Price and K. Rogers, 1991. The use of CA15.3 as a serum tumour marker in breast carcinoma. Eur. J. Surg. Oncol., 17: 16-19.
6. Estrada-Sánchez, D.R.G., M.M. Enriquez and N.V. Castaneda, 2003. Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases. Rev. Invest. Clin., 55: 412-418.
7. Gedik, G.K., P.O. Kiratli, B. Tascioglu and T. Aras, 2006. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma. Saudi Med. J., 27: 317-322.
8. Giai, M., R. Roagna, R. Ponzone, N. Biglia, L. Sgro, M. Perona and P. Sismondi, 1996. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res., 16: 875-881.
9. Gion, M., L. Peloso, R. Mione, G. Vignati and A. Fortunato et al., 2001. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J., 7: 181-190.
10. Gion, M., P. Boracchi, R. Dittadi, E. Biganzoli and L. Peloso et al., 2002. Prognostic role of serum CA15.3 in 362 node-negative breast cancers: An old player for a new game. Eur. J. Cancer, 38: 1181-1188.
11. Gion, M., R. Mione, O. Nascimben, M. Valsecchi, C. Gatti, A. Leon and G. Bruscagnin, 1991. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br. J. Cancer, 63: 809-813.
12. Giovanella, L., L. Ceriani, G. Giardina, D. Bardelli, F. Tanzi and S. Garancini, 2002. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: Comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin. Chem. Lab. Med., 40: 298-303.
13. Hou, M.F., T.J. Huang, J.S. Hsieh, Y.S. Huang and C.J. Huang et al., 1995. Comparison of serum CA15-3 and CEA in breast cancer. Gaoxiong Yi Xue Ke Xue Za Zhi., 11: 660-666.
14. Hou, M.F., Y.L. Chen, T.F. Tseng, C.M. Lin and M.S. Chen et al., 1999. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Kaohsiung J. Med. Sci., 15: 520-528.
15. Martín, A., M.D. Corte, A.M. Alvarez, J.C. Rodriguez and A. Andicoechea et al., 2006. Prognostic value of preoperative serum CA 15.3 levels in breast cancer. Anticancer Res., 26: 3965-3971.
16. Nicolini, A., A. Carpi, P. Ferrari and L. Pieri, 2003. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour. Biol., 24: 275-280.
17. Nicolini, A., A. Carpi, P. Ferrari, L. Anselmi, C. Spinelli, M. Conte and P. Miccoli, 2000. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br. J. Cancer, 83: 1412-1417.
18. Nicolini, A., G. Tartarelli, A. Carpi, M.R. Metelli and P. Ferrari et al., 2006. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer, 6: 269-269.
19. Nicolini, A., P. Ferrari, A. Sagripanti and A. Carpi, 1999. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br. J. Cancer, 79: 1443-1447.
20. Nishimura, R., K. Nagao, H. Miyayama, M. Matsuda, K. Baba, Y. Matsuoka and H. Yamashita, 2003. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast. Cancer, 10: 220-227.
21. O'Brien, D.P., P.G. Horgan, D.B. Gough, R. Skehill, H. Grimes and H.F. Given, 1992. CA15-3: A reliable indicator of metastatic bone disease in breast cancer patients. Ann. R. Coll. Surg. Engl., 74: 9-11.
22. O'Hanlon, D.M., M.J. Kerin, P.J. Kent, R. Skehill, D. Maher, H. Grimes and H.F. Given, 1995. A prospective evaluation of CA15-3 in stage I carcinoma of the breast. J. Am. Coll. Surg., 180: 210-212.
23. Petrie, A. and C. Sabin, 2009. Medical Statistics at a Glance. 3rd Edn., John Wiley and Sons, London, ISBN: 140518051X, pp: 20-48.
24. Ruibal, A., M.G. Pumar and J.I. Arias, 2006. Preoperative serum CA15.3 and CEA levels and clinicalbiological parameters in breast tumors. Rev. Esp. Med. Nucl., 25: 180-183.
25. Tomlinson, I.P., A. Whyman, J.A. Barrett and J.K. Kremer, 1995. Tumour marker CA15-3: Possible uses in the routine management of breast cancer. Eur. J. Cancer, 31: 899-902.
26. Uehara, M., T. Kinoshita, T. Hojo, S. Akashi-Tanaka, E. Iwamoto and T. Fukutomi, 2008. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int. J. Clin. Oncol., 13: 447-451.
27. Velaiutham, S., N.A. Taib, K.L. Ng, B.K. Yoong and C.H. Yip, 2008. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Asian Pac. J. Cancer Prev., 9: 445-448.
28. Wojtacki, J., W.J. Kruszewski, M. Sliwinska, E. Kruszewska and W. Hajdukiewicz et al., 2001. Elevation of serum Ca 15-3 antigen: An early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl. Lek., 58: 498-503.
29. Yildiz, M., B. Oral, M. Bozkurt and A. Cobaner, 2004. Relationship between bone scintigraphy and tumor markers in patients with breast cancer. Ann. Nucl. Med., 18: 501-505.
30. Younsi, N., F. Montravers, C. Philippe, M. Seddiki, S. Uzan, V. Izrael and J.N. Talbot, 1997. CA 15-3 and bone scintigraphy in the follow-up of breast cancer. Int. J. Biol. Markers, 12: 154-157.